Keyphrases
Advanced Malignancies
100%
Irinotecan
100%
Phase I Trial
100%
Epirubicin
100%
Maximum Tolerated Dose
40%
Topoisomerase Inhibitors
40%
Recommended Phase 2 Dose
40%
Neutropenia
20%
High Dose
20%
Dose-limiting Toxicity
20%
Phase I Study
20%
Renal Cancer
20%
Hematotoxicity
20%
Dose Level
20%
Colon Cancer
20%
Stable Disease
20%
Metastatic Tumor
20%
Objective Response
20%
Response Evaluation Criteria in Solid Tumors (RECIST)
20%
Dose-ranging
20%
Ethmoid Sinus
20%
3-cycle
20%
Tumor Evaluation
20%
Adenosquamous Carcinoma
20%
Toxicity Assessment
20%
Pharmacology, Toxicology and Pharmaceutical Science
Irinotecan
100%
Epirubicin
100%
Phase I Trials
100%
Maximum Tolerated Dose
40%
Solid Malignant Neoplasm
40%
Neoplasm
20%
Malignant Neoplasm
20%
Neutropenia
20%
Carcinoma
20%
Colon Carcinoma
20%
Gyrase Inhibitor
20%
DNA Topoisomerase Inhibitor
20%
Toxicity Assessment
20%
Diseases
20%